Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)
NCT00797667 · Merck Sharp & Dohme LLC · PHASE2 · terminated · last registry update 2018-10-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated based on a recommendation of the DSMB following the identification of two patients with significant elevations in serum transaminases” | – | Registry record, Merck Sharp & Dohme LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CALCRL within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-10-03Phase 3 first posted: Novartis Pharmaceuticals, erenumab 70mg/mL (NCT04114630)
- 2019-08-28Results posted on the registry: Allergan, Ubrogepant + Placebo-matching Ubrogepant (NCT02873221)
- 2019-06-03Results posted on the registry: Amgen, Erenumab + Placebo (NCT02542605)
- 2019-05-06Phase 3 first posted: Allergan, Atogepant (NCT03939312)
- 2019-03-13Phase 3 first posted: Pfizer, Zavegepant + Zavegepant matching placebo (NCT03872453)
- 2019-03-13Results posted on the registry: Amgen, Placebo + Erenumab (NCT02630459)
- 2019-03-07Phase 3 first posted: Novartis Pharmaceuticals, Erenumab (NCT03867201)
- 2019-03-05Results posted on the registry: Amgen, Placebo + Sumatriptan (NCT02741310)
- 2019-02-26Phase 3 first posted: Allergan, Atogepant 30 mg + Atogepant 60 mg (NCT03855137)
- 2019-02-11Phase 3 first posted: Amgen, Erenumab Dose 1 + Erenumab Dose 2 (NCT03836040)
- 2019-02-06Phase 3 first posted: Amgen, Erenumab Dose 1 + Erenumab Dose 2 (NCT03832998)
- 2019-01-29Results posted on the registry: Allergan, Ubrogepant + Placebo-matching Ubrogepant (NCT02867709)
- 2019-01-23Phase 3 first posted: Amgen, Erenumab + Placebo (NCT03812224)
- 2019-01-18Results posted on the registry: Amgen, Erenumab + Placebo (NCT01688739)
- 2019-01-18Results posted on the registry: Amgen, Erenumab + Placebo (NCT01723514)
- 2019-01-14Results posted on the registry: Amgen, Erenumab + Placebo (NCT01890109)
- 2019-01-03Results posted on the registry: Allergan, Ubrogepant + Placebo-matching Ubrogepant (NCT02828020)
- 2018-12-20Results posted on the registry: Amgen, Erenumab + Ethynil Estradiol/Norgestimate Oral Contraceptive (NCT02792517)
- 2018-12-17Phase 3 first posted: Allergan, Atogepant + Placebo (NCT03777059)
- 2018-12-06Results posted on the registry: Allergan, Atogepant + Placebo-matching Atogepant (NCT02848326)
- 2018-11-06Phase 3 first posted: Pfizer, Rimegepant + Placebo (NCT03732638)
- 2018-10-09Phase 3 first posted: Allergan, Standard of Care (SOC) Migraine Preventive Medication + Atogepant (NCT03700320)
- 2018-07-10Results posted on the registry: Amgen, Erenumab + Placebo (NCT02456740)
- 2018-07-10Results posted on the registry: Amgen, Erenumab + Placebo (NCT01952574)
- 2018-07-05Results posted on the registry: Amgen, Erenumab + Placebo (NCT02575833)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision